GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Gracell Biotechnologies
The historical timeline of Gracell, a biotech company developing next-generation CAR-T therapies, reflected the potential of its FasTCAR scientific platform. Its history culminated in its acquisition by AstraZeneca in 2024.
Share prices of companies in the market segment - Oncology cell gene therapy
Gracell Biotechnologies is an oncology company that has developed innovative platforms for creating CAR-T therapies, which should be more accessible and faster to manufacture. We've categorized it under "Oncology: Cell Therapy." The chart below shows the dynamics of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Gracell Biotechnologies is a Chinese oncology company developing innovative CAR-T cell therapy for cancer treatment. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Gracell shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
GRCL - Daily change in the company's share price Gracell Biotechnologies
Gracell Biotechnologies' daily share price fluctuations reflect the extreme volatility inherent in cell therapy companies. This metric is a measure of sensitivity to clinical trial data, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Gracell Biotechnologies, before its acquisition by AstraZeneca, was a pioneer in the development of CAR-T therapy. Its story is a classic example of a successful biotech startup whose innovations attracted a pharmaceutical giant. The chart below illustrates the volatility inherent in this sector, where both risks and rewards are high.
Daily change in the price of a broad market stock, index - GURU.Markets
Gracell is a biotech company working on cell therapy. Its shares are a bet on scientific breakthroughs. Their extreme volatility, driven by research data, is part of the dynamics of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Gracell Biotechnologies
Gracell Biotechnologies' year-to-date performance tells the story of its unique CAR-T platform. Its market cap change over the past 12 months reflects progress in its clinical trials, as well as its recent acquisition by AstraZeneca, a fundamental confirmation of the value of its technology, which promises faster and cheaper cell therapy.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Gracell, a biotech company, developed CAR-T therapy. Its acquisition by AstraZeneca was a recognition of its scientific platform. Its past performance reflected both the risks of clinical trials and the potential for breakthroughs, typical of this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gracell Biotechnologies, a company developing next-generation CAR-T cell therapy for cancer, is striving to make this treatment faster and more accessible. Its year-over-year market capitalization growth reflects a bet on a scientific breakthrough in one of the hottest areas of oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Gracell Biotechnologies
Gracell is a biotech company developing CAR-T therapy. Its monthly performance was highly sensitive to clinical trial news. The chart shows typical biotech volatility, which culminated in a sharp spike following the announcement of its acquisition by AstraZeneca.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company developing innovative CAR-T cell therapies for cancer treatment. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its unique technology, which enables faster and more cost-effective CAR-T cell production, is progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Gracell Biotechnologies is a biotech company developing cell therapies. Its shares don't follow the market, but rather move in leaps and bounds following the release of research data. The chart shows the monthly dynamics, which reflect investors' faith in its scientific platform rather than the state of the global economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Gracell Biotechnologies
Gracell Biotechnologies, a biopharmaceutical company developing CAR-T cell therapy for cancer, is experiencing high volatility. Weekly stock performance is driven by news of clinical trials of its innovative platform, reflecting hopes for a breakthrough in cancer treatment.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Gracell and the entire cell therapy sector are moving against a backdrop of scientific breakthroughs and investor anticipation. Regulatory announcements are creating extreme volatility for everyone. The chart will show whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Gracell Biotechnologies is a biotech company developing cell therapies. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that GRCL's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
GRCL - Market capitalization of the company Gracell Biotechnologies
Gracell's stock chart is a financial map of the next generation of cell therapy. The company's market cap reflects the hopes of its CAR-T technology, which enables the development of "living cures" for cancer faster and more affordably. Its dynamics are a barometer of its clinical success and the belief that its approach will make this complex therapy more accessible.
GRCL - Share of the company's market capitalization Gracell Biotechnologies within the market segment - Oncology cell gene therapy
Gracell Biotechnologies is a biotech company developing cell therapies for cancer treatment. Its market cap in the oncology sector reflects its hopes for its innovative CAR-T platforms. The company's size is a bet on its ability to create more accessible and effective treatments.
Market capitalization of the market segment - Oncology cell gene therapy
Gracell Biotechnologies is a Chinese biotech company developing CAR-T therapy for cancer treatment. The chart below shows the overall market capitalization of the entire oncology sector. Its dynamics reflect the global race to create more accessible and effective cell therapies.
Market capitalization of all companies included in a broad market index - GURU.Markets
Gracell is a biotech company developing next-generation CAR-T therapy for cancer. Its market cap is a bet on the future of cell therapy, reflecting the hope that its technology will make this powerful treatment faster and more accessible.
Book value capitalization of the company, segment and market as a whole
GRCL - Book value capitalization of the company Gracell Biotechnologies
Gracell Biotechnologies is an oncology company. Its book value is derived from its equity and cell therapy manufacturing capacity. The chart below shows the material and financial basis for its complex scientific business.
GRCL - Share of the company's book capitalization Gracell Biotechnologies within the market segment - Oncology cell gene therapy
Gracell is a biotech company developing cell therapies. Producing these "living" drugs requires unique facilities. The asset share chart shows how the company is investing in building this complex physical base, which is key to its future.
Market segment balance sheet capitalization - Oncology cell gene therapy
Below you can see the overall book value of the biotech sector. Against this backdrop, Gracell, as a developer of CAR-T therapy, is capital-intensive. Manufacturing "living drugs" requires complex and expensive cleanroom facilities, which poses a high barrier to entry.
Book value of all companies included in the broad market index - GURU.Markets
Gracell Biotechnologies is a biotech company developing CAR-T therapy with a faster manufacturing cycle. The company's assets include a scientific platform and manufacturing know-how. The company's balance sheet is the value of a cell therapy accelerator that could make this revolutionary treatment more accessible in the real world.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Gracell Biotechnologies
Gracell's balance sheet is its cash and scientific platform. Its market capitalization is a bet on its rapid CAR-T therapy technology. The MvsBCap_Co chart shows how much the "hope" for faster and cheaper cell therapy is worth compared to the company's actual assets.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Gracell Biotechnologies is a biotech company developing innovative and faster production technology for CAR-T cell therapy. The chart shows the high speculative valuation of its FasTCAR platform, which promises to make cancer treatment more accessible.
Market to book capitalization ratio for the market as a whole
Gracell Biotechnologies is developing cell therapies for cancer treatment. It's a company at the forefront of biomedical science. Its market valuation is almost entirely divorced from its book value and represents a pure bet on the success of its innovative platform. The chart demonstrates investor optimism about the future of cell therapy.
Debts of the company, segment and market as a whole
GRCL - Company debts Gracell Biotechnologies
Gracell Biotechnologies, a company developing CAR-T therapy, uses debt to finance its innovative clinical programs. This chart shows how the company is raising capital to develop faster and more affordable cell therapies for cancer. In this industry, debt is an investment in technologies that can change patients' lives.
Market segment debts - Oncology cell gene therapy
Gracell Biotechnologies is a biotech company developing innovative CAR-T cell therapy with a faster manufacturing process. This chart shows how the clinical-stage company is funding its cutting-edge, yet capital-intensive, research in an effort to make cell therapy more accessible.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Gracell Biotechnologies
Gracell Biotechnologies is a company developing cell therapies for cancer, one of the most advanced and expensive areas of medicine. This chart shows its dependence on external funding. It reflects the enormous financial risk and investors' bet that its technology can revolutionize oncology.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Gracell Biotechnologies is a biotech company developing CAR-T cancer therapy with a faster production cycle. This could be a significant advantage. The chart shows how the company's debt load to finance this innovative technology compares to the market capitalization of the entire cell therapy sector.
Debt to book value of all companies in the market
Gracell Biotechnologies (GRCL) is a Chinese biotech company developing innovative CAR-T cell therapy for cancer. This chart shows the overall level of debt in the economy. It clearly demonstrates why cutting-edge companies like Gracell are almost always financed through equity rather than debt.
P/E of the company, segment and market as a whole
P/E - Gracell Biotechnologies
This chart for Gracell Biotechnologies, a company developing CAR-T cell therapy, is a measure of faith in its technology. There is no price-to-earnings ratio. The company's valuation is based on the potential of its platform to create faster and more affordable cancer treatments. Its performance depends on the results of clinical trials in China and the US.
P/E of the market segment - Oncology cell gene therapy
This chart shows the average P/E valuation for biotech companies. For Gracell, which works in cell therapy, it serves as a backdrop. It shows the overall level of investor confidence in this cutting-edge technology, providing context for Gracell's valuation, which is a bet on its fast and cost-effective manufacturing platform.
P/E of the market as a whole
Gracell Biotechnologies is a Chinese biotech company developing CAR-T therapy for cancer. It uses its proprietary platform to create faster and more affordable cell therapies. This chart shows the interest in cell therapy and helps understand the market discount the company is pricing due to its Chinese origins and the fierce competition in this field.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Gracell Biotechnologies
Gracell Biotechnologies is a clinical-stage biotech company developing innovative CAR-T cell therapy for cancer. This chart is a barometer of expectations. It reflects analysts' assessments of the potential of the company's technology, which could make CAR-T therapy faster and more accessible, and the chances of its commercialization.
%20P%2FE%20Gracell%20Biotechnologies&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Gracell-Biotechnologies&v=1772657671562 "Chart of the company's future (projected) P/E Gracell Biotechnologies")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Gracell Biotechnologies is developing CAR-T cell therapy for cancer treatment. This chart shows average expectations for the biotech sector. GRCL's position may indicate the extent to which investors believe in its innovative technologies, which could make CAR-T therapy faster, cheaper, and more accessible to patients.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772657671680 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Gracell Biotechnologies is developing cell therapy for cancer, one of the most advanced areas of medicine. The overall market optimism, evident in this chart, is vital for attracting the investment needed to conduct expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772657671745 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Gracell Biotechnologies
Gracell Biotechnologies is a biopharmaceutical company developing innovative CAR-T cell therapies for cancer treatment. This chart reflects cutting-edge technologies in oncology. The losses represent investments in R&D, while the potential profit explosion depends on the success of their unique platform, which could make CAR-T therapy faster and more accessible.
Profit of companies in the market segment - Oncology cell gene therapy
Gracell Biotechnologies is a biotech company developing CAR-T cell therapy for cancer. Profitability in this cutting-edge oncology segment, as this chart shows, is driven by the potential for revolutionary treatments. GRCL aims to make CAR-T therapy faster, cheaper, and more accessible, which could revolutionize the market and help more patients.
Overall market profit
Gracell Biotechnologies, a cancer cell therapy company, is at the forefront of medicine. Its value is determined by scientific breakthroughs and clinical trial successes. The economic cycle, as shown in this chart, doesn't affect the need for treatment, but it does determine the investment climate and the ability to attract funding for groundbreaking research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Gracell Biotechnologies
Gracell Biotechnologies is developing CAR-T therapy for cancer treatment. This chart shows analyst forecasts, which are betting on the success of its innovative technology, which will allow for faster and cheaper cell therapy production.
%20profit%20of%20the%20company%20Gracell%20Biotechnologies&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Gracell-Biotechnologies&v=1772657671977 "Graph of future (projected) profit of the company Gracell Biotechnologies")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Gracell Biotechnologies develops innovative CAR-T cell therapy methods for cancer treatment. The company's technologies aim to make this cutting-edge treatment faster and more accessible. This chart shows the revenue forecast for the oncology sector, reflecting expectations for a breakthrough in cell therapy and its widespread adoption in clinical practice.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772657672000 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Gracell Biotechnologies is a biotech company focused on cancer cell therapy. Its prospects are determined by scientific developments and clinical trial results. The economic environment, reflected in the forecast, influences the company through the availability of financing. In good times, investors are willing to take risks; in bad times, they avoid complex biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772657672020 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Gracell Biotechnologies
Gracell Biotechnologies was a biotech company developing innovative CAR-T cell therapy for cancer. Without sales revenue, its valuation on this chart was purely speculative. It reflected investors' hopes that its technology would make treatment faster and more accessible than existing alternatives.
P/S market segment - Oncology cell gene therapy
Gracell Biotechnologies is developing innovative CAR-T cell therapies for cancer treatment, aiming to make them faster to manufacture and more affordable. The chart shows the average biotech revenue estimate, allowing one to estimate the premium investors are placing on its cutting-edge cell therapy technology.
P/S of the market as a whole
Gracell Biotechnologies is a biotech company developing innovative CAR-T cell therapy for cancer treatment. Its technology aims to improve the effectiveness and accessibility of treatment. The graph of average market revenue estimates highlights the investors' belief in the potential of this scientific breakthrough, which could change the standards of oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Gracell Biotechnologies
Gracell Biotechnologies is a biopharmaceutical company developing innovative cell therapies for cancer. The chart illustrates the high expectations for its next-generation CAR-T technology. It values the company based on the potential for massive future revenues from its faster and more affordable cell therapies.
%20P%2FS%20Gracell%20Biotechnologies&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Gracell-Biotechnologies&v=1772657672135 "The graph of the company's future (projected) P/S Gracell Biotechnologies")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Gracell Biotechnologies is developing innovative CAR-T cell therapies for cancer treatment, aiming to make them faster and more accessible. This chart shows the average future sales estimates for oncology companies. It provides an insight into how the market values Gracell's technology platforms and their potential for treating hematological tumors.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772657672222 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Gracell Biotechnologies is a biotech company developing cell therapies for cancer. It's at the cutting edge of medicine. This graph of overall revenue expectations is irrelevant. GRCL's entire value lies in the success of its scientific platform. The approval of a single therapy could change its fate, regardless of the state of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772657672245 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Gracell Biotechnologies
Gracell Biotechnologies is a clinical-stage biotechnology company developing innovative cell therapies for cancer treatment. Revenue in this chart, if present, likely comes from payments from research partners rather than from sales of finished products, as these are still in development.
Sales of companies in the market segment - Oncology cell gene therapy
Gracell Biotechnologies is a biopharmaceutical company developing innovative CAR-T cell therapies for cancer treatment. The company's technologies are aimed at creating more effective and affordable treatments. This chart shows the sector's total revenue, reflecting the rapid growth and commercial potential of advanced cancer cell and gene therapies.
Overall market sales
Gracell Biotechnologies is a biopharmaceutical company developing cell therapies for cancer treatment. Its market capitalization depends on scientific progress. The overall economic situation, reflected in this chart, influences investor willingness to fund cutting-edge and capital-intensive oncology research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Gracell Biotechnologies
Gracell Biotechnologies is developing innovative CAR-T therapy for cancer treatment, aiming to make it faster to manufacture and more affordable. Its future depends on the success of its unique FasTCAR technology platform. This timeline reflects market expectations for a breakthrough in cell therapy.
%20sales%20of%20the%20company%20Gracell%20Biotechnologies&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Gracell-Biotechnologies&v=1772657672425 "Schedule of future (projected) sales of the company Gracell Biotechnologies")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Gracell Biotechnologies is developing innovative CAR-T cell therapy methods for cancer treatment. The company's technology aims to make this cutting-edge treatment faster and more accessible. The chart shows forecasts for the cell and gene therapy sector. Gracell's success could change the paradigm of cancer treatment.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772657672436 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Gracell Biotechnologies is developing cell therapies for cancer treatment. The future of this innovative company depends on the success of its clinical trials and its ability to scale up production. This schedule, reflecting overall investor sentiment, impacts capital inflows into the capital-intensive cell therapy sector, which is critical for GRCL.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772657672512 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Gracell Biotechnologies
Gracell Biotechnologies is a biotech company developing innovative cell therapy (CAR-T) for cancer treatment. This is a cutting-edge, but very expensive, field of science. This chart shows the company's investment in research to create more accessible and effective cancer treatments.
Market segment marginality - Oncology cell gene therapy
Gracell Biotechnologies is a biopharmaceutical company developing CAR-T cell therapy for cancer treatment. This chart shows the average profitability in the oncology sector. The company's innovative platform, which allows for faster and cheaper CAR-T production, gives it the potential to achieve profitability significantly higher than the industry average.
Market marginality as a whole
Gracell Biotechnologies is a biotech company developing CAR-T cell therapy for cancer treatment. Its innovative platform aims to improve the effectiveness and accessibility of this method. While still in the research stage, Gracell demonstrates how far science is from operating profit, as reflected by its mediocre corporate profitability.
Employees in the company, segment and market as a whole
Number of employees in the company Gracell Biotechnologies
Gracell Biotechnologies is a company developing innovative CAR-T cell therapies for cancer treatment. This chart shows the size of its team of scientists and manufacturing specialists. Creating these complex "living drugs" requires significant investment in highly qualified personnel.
Share of the company's employees Gracell Biotechnologies within the market segment - Oncology cell gene therapy
Gracell Biotechnologies is a biotech company developing CAR-T therapy for cancer treatment, striving to make it faster and more accessible. This is the cutting edge of cell engineering. This chart shows the percentage of exceptional scientists Gracell attracts in this highly complex field of oncology, reflecting its scientific ambitions and potential to create a new standard of care.
Number of employees in the market segment - Oncology cell gene therapy
Gracell Biotechnologies Inc. is a biotechnology company developing innovative CAR-T cell therapies for cancer treatment. The growth of its scientific and manufacturing teams, visible in the graph, reflects progress in clinical trials. This increase is due to the expansion of manufacturing capacity to conduct larger-scale trials.
Number of employees in the market as a whole
Gracell Biotechnologies, acquired by AstraZeneca, was a pioneer in the development of next-generation CAR-T therapies for cancer treatment. The growth of its research team in this chart reflects rapid progress in creating innovative cell products. Successful clinical data and staff expansion made the company an attractive target for one of the global pharma giants.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Gracell Biotechnologies (GRCL)
Gracell Biotechnologies is a biopharmaceutical company specializing in cancer cell therapy (CAR-T). It's at the cutting edge of science. Its market capitalization is based on the potential of its unique technological platform. This metric demonstrates the enormous value the market places on these innovations, based on the cost per scientist working on the development of the next generation of drugs.
%20of%20the%20company%20Gracell%20Biotechnologies%20(GRCL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Gracell-Biotechnologies-GRCL&v=1772657673120 "Chart of market capitalization per employee (in thousands of dollars) of the company Gracell Biotechnologies (GRCL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Gracell Biotechnologies is a biotech company developing innovative cell therapies for cancer treatment. Its value lies in its cutting-edge scientific platform and team of scientists. This chart shows how highly investors value its intellectual capital and R&D potential per employee.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772657673186 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Gracell Biotechnologies is a clinical-stage biopharmaceutical company developing CAR-T cell therapy for cancer. The chart illustrates the valuation of cutting-edge technologies in oncology. Their very high market capitalization per employee reflects the enormous potential of their innovative and sophisticated manufacturing platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772657673228 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Gracell Biotechnologies (GRCL)
Gracell is a biotech company (recently acquired by AstraZeneca) developing "fast" CAR-T therapies for cancer treatment. The company was unprofitable. This chart reflects the net loss (R&D costs) per scientist. This was a bet on their FasTCAR technology platform.
%20Chart%20Gracell%20Biotechnologies%20(GRCL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Gracell-Biotechnologies-GRCL&v=1772657673257 "Company Profit Per Employee (in thousands of dollars) Chart Gracell Biotechnologies (GRCL)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Gracell Biotechnologies is a biotech company developing CAR-T therapy for cancer treatment. Its key feature is its technology, which allows for faster and cheaper cell production. This graph shows the cash burn per employee during R&D. It serves as a benchmark for assessing how intensively Gracell is investing in validating its innovative manufacturing platform.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772657673304 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Gracell Biotechnologies is a clinical-stage biotech developing a new generation of cell therapy (CAR-T) for cancer treatment, striving to make it faster and cheaper. The company is not profitable. This chart shows the loss per employee, reflecting the R&D phase of investment in cutting-edge, but very expensive, cancer treatments.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772657673335 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Gracell Biotechnologies (GRCL)
Gracell Biotechnologies is a biotech company developing cell therapies for cancer treatment. This graph will reflect progress in monetizing its unique technology. The increase in revenue per employee will likely be the result of a strategic partnership with a major pharmaceutical company.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Gracell-Biotechnologies-GRCL&v=1772657673349 "Sales chart per company employee Gracell Biotechnologies (GRCL)")
Sales per employee in the market segment - Oncology cell gene therapy
Gracell (GRCL) is a clinical-stage biotech (acquired by AstraZeneca) developing cell therapy (CAR-T) for cancer treatment. The company has no approved products or commercial revenue. This chart doesn't reflect their value. Staff productivity here would be zero, as the entire staff is focused on R&D.
Sales per employee for the market as a whole
Gracell Biotechnologies is a biotech company developing CAR-T cell therapy for cancer treatment. It has extensive R&D. During the clinical trial phase, revenue is minimal, but the R&D staff is large. This metric is important as a future indicator: if successful, it will show how effectively the company will be able to commercialize its research.
Short shares by company, segment and market as a whole
Shares shorted by company Gracell Biotechnologies (GRCL)
Gracell (GRCL) is a biotech company working in CAR-T cancer therapy. Their innovation is an attempt to make CAR-T therapy faster, cheaper, and more accessible to patients. This figure reflects bearish bets. Do bears doubt their technology will prove superior to CAR-T therapies from Big Pharma?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Gracell-Biotechnologies-GRCL&v=1772657673635 "Short Shares Chart for the Company Gracell Biotechnologies (GRCL)")
Shares shorted by market segment - Oncology cell gene therapy
Gracell Biotechnologies is a biotech company developing cell therapy (CAR-T) for cancer treatment. Their technology aims to reduce the cost and speed up this complex process. This chart illustrates the overall bearish sentiment across the cell and gene therapy sector. High values indicate that investors doubt the commercial viability of these expensive and complex treatments.
Shares shorted by the overall market
Gracell Biotechnologies is at the forefront of cell therapy, a field with enormous potential but requiring significant R&D investment. Its survival depends on investor confidence. When this graph signals rising fear, funding for speculative biotechs often evaporates, threatening vital research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Gracell Biotechnologies (GRCL)
Gracell was a biotech company developing CAR-T therapy for cancer. This graph represents the M&A "pulse." Investor interest "overheated" to the extreme and plateaued. This was not due to trial data, but to the news of the company's acquisition by the giant AstraZeneca, reflecting the high valuation of their scientific platform.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Gracell-Biotechnologies-GRCL&v=1772657673806 "RSI 14 indicator chart for the company's stock Gracell Biotechnologies (GRCL)")
RSI 14 Market Segment - Oncology cell gene therapy
Gracell Biotechnologies is a biotech innovator (China) that developed a "fast" CAR-T therapy (FasTCAR) for the treatment of blood cancer (acquired by AstraZeneca). The "Oncology cell gene therapy" sector thrives on R&D news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: was Gracell's acquisition a sign of recognition of their technology or a general "overheating" in biotech?
RSI 14 for the overall market
For Gracell Biotechnologies, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GRCL (Gracell Biotechnologies)
Gracell is a biotech company (acquired by AstraZeneca) that developed innovative CAR-T platforms (FasTCAR, TruUCAR) for cancer treatment. This chart shows the average analyst forecast. Their targets were based on clinical data, the potential of its rapid CAR-T manufacturing technology, and the price of the deal with AstraZeneca.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GRCL-Gracell-Biotechnologies&v=1772657673930 "A chart showing analyst consensus forecasts for the expected stock price. GRCL (Gracell Biotechnologies)")
The difference between the consensus estimate and the actual stock price GRCL (Gracell Biotechnologies)
Gracell is the biotech company that "hacked" CAR-T. Their R&D platform (FasTCAR) enables cell therapy production "overnight," not in weeks. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, which is now tied to the acquisition price of the giant AstraZeneca.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GRCL-Gracell-Biotechnologies&v=1772657673944 "A chart showing the difference between the consensus forecast and the actual stock price. GRCL (Gracell Biotechnologies)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Gracell (GRCL) is a biotech company that has developed an "accelerated" technology (FasTCAR) for producing cell therapy (CAR-T) in 1-2 days instead of weeks. This chart shows general expectations for the cell oncology sector. It reflects whether experts believe technological breakthroughs will make CAR-T more accessible.
Analysts' consensus forecast for the overall market share price
Gracell (GRCL) is a Chinese biotech company that wanted to make CAR-T cheaper. Their FasTCAR platform aimed to produce cancer cell therapy in days, not weeks. This chart shows the overall risk appetite. It reflects the willingness of investors to invest in breakthrough R&D platforms, especially from technologically advanced China.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Gracell Biotechnologies
Gracell is China's CAR-T 2.0. It's a biotech R&D company (China) developing cell therapy (CAR-T) for cancer. Their signature feature is speed (FasTCAR): they claim they can produce a drug (from a patient's cells) in 24 hours (not weeks). This chart is a summary of their R&D, reflecting the (speculative) valuation of their technology and geopolitical risks.
AKIMA Market Segment Index - Oncology cell gene therapy
Gracell (GRCL) focuses on oncology through cell-based gene therapy. Their signature feature is the FasTCAR technology, which allows CAR-T therapy to be produced in just 24 hours, not weeks. This demonstrates the speed of their R&D. This chart compares their composite index to the sector average.
The AKIM Index for the overall market
Gracell Biotechnologies is a Chinese biotech company, a pioneer in rapid-release CAR-T therapy (FasTCAR). It was acquired by AstraZeneca. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this successful innovation story from China compares to overall economic trends.
